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ABSTRACT
Renal cell carcinoma (RCC) is increasing in incidence, and a complete cure 
remains elusive. While immune-checkpoint antibodies are promising, interferon-based 
immunotherapy has been disappointing. Tryptophan metabolism, which produces 
immunosuppressive metabolites, is enhanced in RCC. Here we show indolamine-2,3-
dioxygenase-1 (IDO1) expression, a kynurenine pathway enzyme, is increased not 
only in tumor cells but also in the microenvironment of human RCC compared to 
normal kidney tissues. Neither kynurenine metabolites nor IDO inhibitors affected the 
survival or proliferation of human RCC or murine renal cell adenocarcinoma (RENCA) 
cells in vitro. However, interferon-gamma (IFNγ) induced high levels of IDO1 in both 
RCC and RENCA cells, concomitant with enhanced kynurenine levels in conditioned 
media. Induction of IDO1 by IFNα was weaker than by IFNγ. Neither the IDO1 inhibitor 
methyl-thiohydantoin-DL-tryptophan (MTH-trp) nor IFNα alone inhibited RENCA 
tumor growth, however the combination of MTH-trp and IFNα reduced tumor growth 
compared to IFNα. Thus, the failure of IFNα therapy for human RCC is likely due to 
its inability to overcome the immunosuppressive environment created by increased 
IDO1. Based on our data, and given that IDO inhibitors are already in clinical trials for 
other malignancies, IFNα therapy with an IDO inhibitor should be revisited for RCC.
INTRODUCTION
Kidney cancer is one of the few malignancies 
that show an increasing incidence in the United States, 
possibly due to the prevalence of obesity and the metabolic 
syndrome in the Western world [1, 2]. The treatment of 
metastatic RCC has evolved from the early, and relatively 
ineffective, use of single-agent immunomodulatory agents 
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such as interferon-alpha (IFNα) and interleukin-2 (IL-2) 
[3, 4], to the use of targeted therapeutics such as the multi-
kinase and mTOR inhibitors as well as the checkpoint 
inhibitors. Nevertheless, the continued lack of therapeutic 
targets that produce a sustained remission for this disease 
has led our group and others to search for novel and 
heretofore untested approaches based on its metabolic 
features.
In mammalian tissues, the essential amino acid 
tryptophan can be metabolized to serotonin, melatonin, 
kynurenic acid, picolinic acid, and NAD+, the latter 
three compounds being produced via the kynurenine 
pathway, which is the major pathway for tryptophan 
metabolism [5, 6]. The kynurenine pathway of tryptophan 
metabolism influences the innate and adaptive immune 
systems through production of the metabolites kynurenine, 
3-hydroxy kynurenine (3-HK), 3-hydroxyanthranilic acid 
(3-HAA) and quinolinate via IFNγ-induced indolamine-
2,3-dioxygenase-1 (IDO1) activity [6]. The known effects 
of kynurenine metabolites include inhibition of T-cell 
proliferation, downregulation of NK cell responses and 
activation of T regulatory (Treg) cells [6]. By combining 
non-targeted metabolomic and proteomic analysis of 
human RCC tissue, we have recently uncovered striking 
upregulation of the kynurenine pathway of tryptophan 
metabolism in clear cell RCC (ccRCC) [7], confirming our 
metabolomics data from urine analysis in ccRCC patients 
[8]. These data suggest that one of the most proximal 
enzymes in the kynurenine pathway is likely up-regulated 
in ccRCC. Concomitantly and conspicuously, the other 
branches of tryptophan metabolism (for example serotonin 
and indole-3-acetate) are markedly downregulated in RCC 
[7].
The most proximal enzyme in the kynurenine 
pathway that is expressed in tumors and immune cells is 
IDO1 [9], while its paralog IDO2 is expressed in dendritic 
cells. These two enzymes act via multiple mechanisms to 
enable tumors to evade critical immune surveillance [10, 
11]. In light of these associations and our previous data, 
we asked whether inhibition of the kynurenine pathway in 
vivo inhibits tumor growth in a mouse model of immune-
stimulated kidney cancer. We now show that growth of 
several human RCC cell lines as well as RENCA cells 
incubated in the presence of IDO inhibitors, kynurenine, 
or its metabolites, is not altered in vitro, yet growth of 
RENCA tumors in immune-competent mice in vivo 
is attenuated when IFNα is administered concurrently 
with the competitive IDO1 and IDO2 inhibitor methyl-
thiohydantoin-DL-tryptophan (MTH-trp). Our results 
suggest that the mechanism of this effect is associated 
with the production of IDO1 by endothelial, tumor and 
CD68+ immune cells leading to tryptophan catabolism 
into kynurenine, which can be inhibited by MTH-trp. 
In light of our data, it is logical to revisit IFN-based 
immunotherapy for RCC but in future trials it should be 
combined with IDO1 inhibitors.
RESULTS
IDO1 expression is increased in RCC compared to 
adjacent normal tissue
Of the several enzymes that convert tryptophan 
to kynurenine, IDO1 is widely expressed across tissues 
whereas TDO2 is expressed primarily in the liver 
[12]. We therefore examined the distribution of IDO1 
in ccRCC tumors of grades 2, 3 and 4, as well as in 
adjacent normal tissue by immunohistochemistry, and 
we measured IDO1 mRNA levels by qRT-PCR. RCC 
tissues showed upregulated IDO1 mRNA expression 
compared with adjacent normal kidneys (Figure 1). IDO1 
staining localized to endothelial cells, tumor cells and 
inflammatory cells resembling tissue macrophages or 
myeloid cells in grades 2 and 3 RCC (Table 1; Figure 1; 
raw data in Table 2). Large areas of necrosis in all grade 4 
RCC samples precluded an accurate assessment of staining 
in these tissues (data not shown). The staining patterns 
were distinct in grades 2 vs. 3: cells in microvessels within 
the parenchyma accounting for a greater proportion of the 
staining in grade 3 tumors and cells lining small venules 
accounting for most of the staining in grade 2 tumors 
(Figure 1). The apparent IDO staining of macrophages was 
assessed by staining serial sections of RCC for CD68, an 
antigen expressed primarily by macrophages/monocytes 
and dendritic cells as well as by some neutrophils and 
large lymphocytes. Most CD68-positive cells were 
Table 1: Immunohistochemistry staining score of renal cell carcinoma (RCC) and adjacent normal kidney tissue
Antibody IDO11 IDO1 IDO1 CD682
Tissue Endothelial cells Neoplastic cells Interstitial cells Interstitial cells
Kidney 0±0 0±0 0±0 0.67±0.28
Grade 23 2.00±1.00 0.67±0.58 1.00±0 2.50±0.50
Grade 3 2.33±0.58 0±0 1.00±0 3.83±1.26
1Score for indolamine-2,3-dioxygenase 1 (IDO1): 0=no staining, 1=1-10%, 2=10-20%, 3=20-40% staining, respectively
2Score for CD68: 0=no staining, 1=1-10%, 2=10-20%, 3=20-30%, 4=30-40%, 5=40-50% positive interstitial cells 
3Grade of RCC
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interstitial and more abundant in grades 2 and 3 compared 
to normal (Figure 1; Table 1). Some CD68-positive cells 
were intimately associated with blood vessels, including 
capillaries. Indeed, there were more CD68-positive 
interstitial cells than IDO1-positive interstitial cells in 
RCC tissues (Table 1), but virtually all the IDO1-positive 
interstitial cells localized to CD68+ areas (Figure 1), 
suggesting that IDO1 is present in inflammatory cells as 
well as in tumor and endothelial cells.
Table 2: Immunohistochemistry staining score of RCC and adjacent normal kidney tissue.
Antibody IDO13 IDO1 IDO1 CD684
Tissue Endothelial cells Neoplastic cells Interstitial cells Interstitial cells
Kidney Neg1 0 0 0 n/a
Kidney-1 0 0 0 0.5
Kidney-2 0 0 0 0.5
Kidney-3 0 0 0 1
Grade 22 Neg 0 0 0 0
Grade 2-1 1 0 1 2.5
Grade 2-2 3 1 1 3
Grade 2-3 2 1 1 2
Grade 3 Neg 0 0 0 0
Grade 3-1 2 0 1 4
Grade 3-2 2 0 1 5
Grade 3-3 3 0 1 2.5
1Neg=secondary antibody only 
2Grade of renal cell carcinoma (RCC)
3Score for IDO1: 0=no staining, 1=1-10%, 2=10-20%, 3=20-40% staining, respectively
4Score for CD68: 0=no staining, 1=1-10%, 2=10-20%, 3=20-30%, 4=30-40%, 5=40-50% positive interstitial cells
Figure 1: IDO1 is upregulated in human RCC. A., C., E., G. Immunohistochemistry with IDO1 antibody of normal human 
kidney and RCC (grades 2 and 3). A. Adjacent normal kidney C. Grade 2 RCC E. Grade 3 RCC G. Grade 2 RCC without IDO1 antibody. 
B.,D.,F.,H. Immunohistochemistry with CD68 antibody in serial sections to A, C, E and G were stained for CD68. B. Adjacent normal 
kidney D. Grade 2 RCC F. Grade 3 RCC H. Grade 2 RCC without CD68 antibody. I. Expression of IDO1 mRNA measured by qPCR in 
grades 1-4 of RCC and adjacent normal kidney tissues. ***P < 0.0001. Scale bar = 100 µm.
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Kynurenine pathway metabolites and IDO 
inhibitors have minimal effects on RCC viability 
in vitro
In light of our earlier finding that kynurenine 
pathway metabolites are upregulated in RCC [7] and 
based on previous reports demonstrating toxicity of these 
metabolites for murine and human T-cells [6, 17, 18], we 
first evaluated the direct effects of the kynurenine pathway 
metabolites 3-HAA, 3-HK, kynurenine, quinolinate and 
kynurenic acid on the viability of the three human RCC 
cell lines 786-O, ACHN and Caki-1. There were minor 
effects of just three metabolites, but only on ACHN cell 
viability (Figure 2). In addition, the IDO1 and/or IDO2 
competitive inhibitors 1-L-MT, 1-D-MT and MTH-trp 
had no effects on cell growth across human and mouse 
renal cancer cell lines (Figure 3). Thus, neither tryptophan 
metabolites nor IDO inhibitors affect the viability or 
proliferation of RCC cells in vitro. 
IDO1 expression in RCC cell lines is stimulated 
by interferons
The transcription of IDO1 mRNA, which is mainly 
expressed in RCC rather than normal kidney (Figure 1), 
has been shown to be induced by IFNγ [19]. Because 
early (and still extant) chemotherapies for advanced RCC 
include IFNα [3, 20], we examined the temporal induction 
of IDO1 by both IFNγ and IFNα in human (ACHN and 
A498) and mouse RCC (RENCA) cells. Levels of IDO1 
were markedly increased in RENCA cells by mouse 
IFNγ (100 ng/ml), and in two human RCC cell lines by 
human IFNγ (50 ng/ml), with maximal induction after 48-
72h (Figure 4A). As expected, there was no effect of the 
IDO1/2 inhibitor MTH-trp on levels of IFNγ-stimulated 
IDO1 protein (Figure 4B). The expression of IDO1 was 
also induced by IFNα in human RCC and RENCA cells 
in vitro, but maximal induction occurred after 24h (Figure 
5), which was earlier than the IDO1 induction by IFNγ 
(Figure 4). In addition, the relative magnitude of IDO1 
protein induction by IFNα was considerably less than that 
initiated by IFNγ (Figure 5). A similar phenomenon of 
differential IFN regulation of downstream effectors has 
been reported in primary human fibroblasts [21].
Kynurenine pathway metabolism in vitro is 
increased by IFNγ and attenuated by IDO 
inhibition
To determine whether inhibition of IDO attenuates 
the kynurenine pathway in RCC cells in vitro, and as a 
prelude to in vivo studies, we evaluated the dose-response 
of the kynurenine pathway to IFNγ which, of the two 
IFNs, evoked the higher induction of IDO1. Incubation 
of 786-O cells with IFNγ stimulated maximal production 
of kynurenine (Figure 6A). We subsequently evaluated 
the ability of the commonly-used specific IDO1 inhibitor 
1-L-MT [14] as well as MTH-trp, which is a competitive 
inhibitor of IDO1 and IDO2 [22, 23], to inhibit the 
activity of IFNγ-induced IDO1. While treatment with 
1-L-MT (100 µM) did not reduce the IFNγ-induced 
production of kynurenine (data not shown), an MTH-trp 
dose curve revealed that 100 µM MTH-trp (25.9 µg/ml) 
realized maximal inhibition of kynurenine production 
(Figure 6B). We then evaluated this process in several 
RCC cell lines and RPTEC cells. Treatment with IFNγ 
induced kynurenine secretion and significantly reduced 
tryptophan concentrations in the media from ACHN, 
A-498 and RENCA cells (Figures 6C-6E), while IFNγ 
Table 3: PCR primers used for quantitative PCR.
Accession Number Gene Forward and Reverse Primers (5’-3’) Tm1 (oC) E2 (%)
NM_005651 hTDO2 GCACTTCAGGGAGCATTGATTCACTCACAGTTGATCGCAG 64 103
hIDO1 [13] GGTCATGGAGATGTCCGTAA ACCAATAGAGAGACCAGGAAGAA 62 97
NM_019911 mTdo2 ATGGCTGGAAAGAACACCTG CATCAAACAAGCAGAGCAGC 63 79
mIdo1 [14] GTACATCACCATGGCGTATGCGAGGAAGAAGCCCTTGTC 60 88
NM_001289726 mGapdh TGATGGGTGTGAACCACGAGAAGTCGCAGGAGACAACCTG 63 53
Rn18S [15] ACGGCTACCACATCCAAGGACCAATTACAGGGCCTCGAAA 60 90
PPIA [16] ACCGCCGAGGAAAACCGTGTATGCTGTCTTTGGGACCTTGTCTGC 64 95
RPS13 [16] TCGGCTTTACCCTATCGACGCAGACGTACTTGTGCAACACCATGTGA 64 101
1Annealing and extension temperature.
2Primer pair efficiency (E).
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induced kynurenine secretion by RPTEC cells was 
minimal, with no effect on tryptophan concentrations 
(Figure 6F). Notably the combination of MTH-trp and 
IFNγ significantly inhibited kynurenine production in all 
cell lines compared to IFNγ treatment (Figures 6C-6F). 
Thus the kynurenine pathway is activated in RCC cells in 
response to IFNγ and can be inhibited by the dual IDO1 
and IDO2 inhibitor MTH-trp. 
Figure 2: Minimal effect of tryptophan metabolites 3-hydroxyanthranilic acid (3-HAA), 3-hydroxy-DL-kynurenine 
(3-HK), kynurenine, quinolinate and kynurenic acid on viability of human RCC cell lines. Equal numbers of cells were 
plated in 96-well plates, treated (n = 6 wells/treatment) for three days with different doses of each metabolite then cell viability measured 
using an MTT assay. Data are an average of two independent experiments and representative of at least three experiments. *P ≤ 0.05.
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Tumor growth in vivo is inhibited by MTH-trp 
and IFNα
Given that (i) IDO1 expression is elevated in RCC 
(Figure 1), (ii) kynurenine pathway metabolites are 
increased in RCC [7], and (iii) the immunomodulatory 
agent IFNα can induce IDO1 expression in RCC cells 
(Figure 5), we conducted an in vivo study using RENCA 
cells in syngeneic Balb/c mice treated with IFNα and 
MTH-trp. IFNα rather than IFNγ was utilized in these 
experiments as it has previously been used to treat RCC in 
Figure 3: Minimal effect of the IDO inhibitors methyl-thiohydantoin-DL-tryptophan (MTH-trp), 1-methyl-L-
tryptophan (1-L-MT) and 1-methyl-D-tryptophan (1-D-MT) on human RCC and RENCA cell growth. Equal numbers 
of cells were plated in 96-well plates, treated (n = 6 wells/treatment) for three days with different IDO inhibitors or 0.1% DMSO, then final 
cell numbers measured using the methylene blue assay. Data are representative of three independent experiments.
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Figure 4: IFNγ induces IDO1 in RCC and normal renal proximal tubular epithelial cells, and levels are unaffected 
by IDO inhibition. A. Human RCC cells (A-498; ACHN; 50 ng/ml hIFNγ) or RENCA cells (100 ng/ml mIFNγ) were incubated with 
IFNγ for the times indicated, followed by immunolotting for IDO1. B. Human RCC cells, RENCA cells, or normal human RPTEC were 
incubated with IFNγ in the presence or absence of MTH-trp for 72 h followed by immunoblotting for IDO1. Data shown are representative 
of at least two independent experiments.
Oncotarget66547www.impactjournals.com/oncotarget
Figure 5: IFNα induces IDO1 in human RCC and RENCA cells. The indicated RCC cells were incubated with IFNα or IFNγ 
for the times indicated and immunoblotted for IDO1 and vinculin or β-actin. A. A498 cells stimulated with either IFNγ for 72h or IFNα for 
24-72h. Chemiluminescent exposure times were the same for all samples. B. A498 cells stimulated with IFNα for 24-72h from A. after a 
longer exposure. C. Caki-1 cells stimulated with IFNα for 24-72h. D. Caki-1 cells stimulated with either IFNγ for 72h or IFNα for 24h. E. 
RENCA cells stimulated with IFNα for 24-72h. F. RENCA cells stimulated with IFNγ from Figure 4A and RENCA cells stimulated with 
IFNα from Figure 5E exposed for the same length of time. Data shown are representative of two independent experiments.
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Figure 6: The IFNγ-induced increase in tryptophan catabolism is inhibited by MTH-trp. Cells were treated as indicated 
for 72 h and conditioned media subjected to HPLC to measure tryptophan (TRP) and kynurenine (KYN) levels using authentic standards. 
A. Dose curve for IFNγ (0-50 ng/ml) added to 786-O cells (n = 2) alone, or B. IFNγ (50 ng/ml) in combination with MTH-trp (0-100 μM). 
Media was collected from C. ACHN, D. A-498, E. RENCA and F. RPTEC cells (n = 3) treated with either human IFNγ (50 ng/ml) or mouse 
IFNγ (100 ng/ml) with or without MTH-trp (100 µM). Control cells (Con) were treated with 0.1% DMSO only. Results are representative 
of two independent experiments and expressed as concentration in media per 1 x 106 (1M) cells. **P < 0.01; *P < 0.05. BD: below limits 
of detection (5 µM).
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the clinic. While neither MTH-trp nor IFNα alone inhibited 
tumor growth, the combination of IFNα and MTH-trp 
significantly reduced both the rate of tumor growth and 
the final tumor weight compared to treatment with IFNα 
alone (P < 0.05; Figures 7A and 7B). The combination of 
IFNα and MTH-trp also reduced the tumor growth rate 
compared to that in control animals (P = 0.07; Figure 
7A) and the MTH-trp treated animals (P = 0.07; Figure 
7A) although this did not reach the P < 0.05 threshold. At 
necropsy, IDO1 protein expression was higher in nearly 
all of the RENCA tumors compared to that in three normal 
kidneys (Figure 7B), similar to the elevated expression of 
IDO1 in human RCC (see Figure 1).
MTH-trp does not alter the topology or 
composition of the intratumoral immune 
microenvironment in vivo
Previous work has shown that inhibition of IDO-1 
restores activity of T cells in the tumor environment [24], 
but the potential of IDO inhibition to alter the overall 
tumor immune landscape has not been determined. 
We therefore performed a second in vivo study using 
the heterotopic RENCA model where animals were 
treated with vehicle or with MTH-trp alone. After 10 d 
of treatment, the tumors were harvested, a section from 
each was fixed for routine pathological analysis, and the 
rest was dissociated into a suspension of single cells to 
interrogate their stromal, immune and inflammatory 
Figure 7: The IDO1 inhibitor MTH-trp enhances the anti-tumor effect of IFNα in vivo. Male Balb/cJ mice (n= 37) were 
injected subcutaneously with 500,000 RENCA cells on day 0. Treatments were initiated on day 7 and mice were euthanized on day 21; 
MTH-trp (4 mg/mouse) was injected daily (IP); IFNα (25,000U) was injected 5 d/week (SC). A. Resected tumors were measured with 
calipers and the relative tumor growth rate for each mouse is plotted as size on day 21/size on day 7. Median data points are indicated 
with a horizontal line. *P < 0.07 compared to Con (control) and MTH. *P < 0.05 compared to IFNα. B. Final weights of resected RENCA 
tumors. *P < 0.05 compared to IFNα. *P < 0.1 compared to Con. Data are least squares means ± standard error. C. Proteins extracted from 
Balb/c mouse kidneys or RENCA tumors from control mice or mice treated with MTH-trp, IFNα or IFNα+MTH-trp were probed for IDO1 
expression by immunoblotting. 
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composition by multi-parameter flow cytometry. 
The tumors were extremely anaplastic with marked 
anisocytosis and anisokaryosis, frequent mitoses, 
bizarre giant cells/syncytia, and marked invasion into 
surrounding subcutaneous tissues. The larger tumors had 
extensive areas of necrosis with secondary neutrophilic 
and histiocytic inflammation. The subcutaneous tissues 
surrounding the tumors contained mild to moderate 
numbers of macrophages with fewer lymphocytes and 
plasma cells. Among the subsets analyzed by flow 
cytometry, there was substantial variation in the number 
of tumor-infiltrating leukocytes. Neither the total number 
of intratumoral immune cells nor the relative number of 
granulocytes (GR1+, CD11b+, or GR-1/CD11b+), B cells 
(CD20+), T cells (CD3+), dendritic cells (CD11c+), NK 
cells (NK1.1+), NK-T cells (NK1.1+/ CD3+), or fibroblast 
and endothelial stromal cells (PDGFRα+) in the tumors 
was changed by MTH-trp treatment. 
TDO2 is not elevated in RCC cells and tissues
Because IDO1, IDO2 and TDO2 all catabolize 
tryptophan to kynurenine, any of these enzymes could 
activate the kynurenine pathway in RCC, a possibility 
we evaluated by qRT-PCR. Expression of IDO2 mRNA 
was detected in human and mouse kidney, but not in 
grade 3 RCC or RENCA tumors (data not shown). As 
expected, we found that TDO2 mRNA was most abundant 
in both human and mouse liver (Figures 8A and 9A). 
There was no difference in hTDO2 mRNA expression 
between normal kidney and grade 3 RCC tissues (P = 
0.5; Figure 8A). However, hIDO1 mRNA was expressed 
at higher levels than TDO2 in normal kidney and was 
elevated further in grade 3 RCC (Figures 8B and 8C). 
Similarly, mIdo1 mRNA was expressed at higher levels 
than mTdo2 in normal kidney and RENCA tumors (Figure 
9B). Combined with our data showing elevated IDO1 
protein and mRNA expression in grades 2, 3 and 4 RCC 
compared to normal kidneys (see Figure 1), we conclude 
that TDO2 and IDO2 are unlikely to be involved in the 
grade-dependent elevation of the kynurenine pathway that 
occurs in RCC.
DISCUSSION
Long before the recent discovery and therapeutic use 
of antibodies against immune checkpoints, patients with 
RCC were treated with the immunomodulatory agents 
IFNα and IL-2 [3, 4]. In addition to the disappointing 
responses of these cancers to such treatments, patients 
undergoing these therapies experienced serious adverse 
effects that, with the advent of targeted therapies 
like mTOR and VEGFR inhibitors, led to the near-
abandonment of IFNα and IL-2 as mainstream RCC 
therapies [20, 25, 26]. However, the partial success of 
immunomodulatory agents, as well as several recent 
successful clinical trials using antibodies against immune 
checkpoints, has underscored the immunogenicity of RCC 
[27] such that the use of interferons should be revisited. 
Our data from the current study support the notion that 
at least one reason for the common failure of IFNα 
therapy in treatment of human disease is due to its further 
induction of IDO1, which is already upregulated in RCC 
as evidenced by such high levels of immunosuppressive 
kynurenine pathway metabolites that they appear in the 
urine of RCC patients [8]. On the other hand, the novel 
idea of using the combination of IFNα and an IDO1 
inhibitor results in salutary effects on tumor growth in 
mice: in this situation the immune stimulatory properties 
of IFNα are left intact while the immunosuppressive 
activities (through the generation of kynurenine and its 
metabolites) are blocked. Whether this will hold true in 
human disease is a question which should be addressed in 
future clinical trials.
Earlier non-targeted metabolomics studies in our 
laboratory showed increased levels of kynurenine pathway 
metabolites in the urine of ccRCC patients [8], as well 
as in human RCC xenografts [28] and RCC tissues [7]. 
Those findings served as the basis for the current study 
in which we evaluated whether the kynurenine pathway 
was operative and could be therapeutically targeted 
in RCC. The enzymes most proximal to tryptophan, 
which result in activation of this pathway, are IDO1, 
IDO2 and TDO2, and all of these enzymes have been 
shown to be upregulated in a variety of cancers [10, 29]. 
Upregulation of IDO can inhibit T-cell activation through 
a combination of tryptophan starvation as well as via the 
action of kynurenine and its metabolites 3-HK, 3-HAA 
and quinolinate [11, 30, 31]. Plasmacytoid dendritic cells 
expressing IDO can also activate mature Treg cells and 
convert naïve T-cells into Treg cells [11, 30], where IDO 
downregulates production of IFNα by dendritic cells [11]. 
Our data suggest that MTH-trp reduces IDO activity and 
production of kynurenine pathway metabolites and thus 
potentially prevents or reverses these effects. Moreover, 
we also demonstrate that there is substantial IDO1 but 
relatively little TDO2, in human RCC tissue and RENCA 
tumors, suggesting that the TDO2-driven immune 
suppression mechanism is less relevant to RCC.
Tumor endothelial cells appear to express IDO1 in 
human RCC as has been previously suggested [13]. We 
also find that IDO1 was produced by tumor cells and by 
tumor-associated interstitial cells that may be CD68+ 
macrophages or may be other “round” cells observed 
in these sections, including non-macrophage myeloid 
derived cells. Our finding that IDO1 immunoreactivity 
was confined to tumor blood vessels (and not in adjacent 
normal kidney vessels), suggests that RCC tumors are 
using the well-described immunosuppressive mechanism 
of intra-tumoral activation of IDO1 expression and 
enhancement of the local kynurenine pathway [6]. 
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Figure 8: Indolamine-2,3-dioxygenase 1 (IDO1) is expressed at higher levels than tryptophan-2,3-dioxygenase (TDO2) 
in kidney and RCC tissues. RNA was reverse transcribed and subjected to qPCR for IDO1 and TDO2 mRNA and corrected for PPIA 
and RPS13 mRNA levels. A. Human liver (n = 1), grade 3 RCC (n = 5) and matched normal kidney (n = 5), RPTEC (n=1), A-498 (n = 1), 
786-O (n = 1), ACHN (n = 1) and Caki-1 (n = 1). B. IDO1 mRNA quantity in the same samples analyzed in A. C. Ratio of IDO1/TDO2 
mRNA in the same samples analyzed in A.
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Figure 9: Mouse IDO1 expression levels are much higher than TDO2 in kidney and RENCA tumors. Mouse Tdo2 
expression was corrected for Rn18S and Gapdh mRNA levels. Mouse liver (n = 1), mouse kidney (n = 1) and RENCA tumors (n = 4) from 
control (Con), MTH-trp (MTH) or IFNα treated mice.
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Consistent with these data, kynurenine and its metabolites 
individually had no effect on RCC cell growth in vitro 
while many of these compounds are toxic to immune cells 
[6]. 
Given what is known about alterations in the 
immune environment which occur in response to 
tryptophan catabolism [32], we expected that the major 
effects of MTH-trp would manifest as an alteration in the 
tumor’s immune environment; however our data (at least 
after 10 days) do not support that hypothesis as treatment 
of the animals with MTH-trp did not alter the anatomical, 
topological, or phenotypic composition, nor the absolute 
number tumor-infiltrating immune cell subsets. Thus it is 
likely that tryptophan metabolites, or the administration of 
IFNα and an IDO1 inhibitor, are in the short term causing 
their observed effects upon tumor growth by indirect 
actions upon immune cells, such as altered functionality of 
intratumoral leukocytes. Further and longer-term studies 
are required to fully evaluate the effects of MTH-trp on 
the functionality of these subsets, particularly effector T 
cells in renal cell carcinoma in general and in the RENCA 
model in particular. 
There are several ongoing clinical studies using IDO 
inhibitors, either singly or in combination, in refractory 
RCC. Two combination IDO inhibitor and checkpoint 
antibody studies (clinicaltrials.gov NCT02178722, 
NCT02318277), a combination IDO inhibitor and JAK 
inhibitor study in advanced solid tumors (NCT02559492), 
and an IDO inhibitor alone study on refractory solid 
tumors (NCT02048709) are all recruiting. However, 
none of these studies are complete and none have utilized 
interferon in combination with an IDO inhibitor; thus our 
pre-clinical study is unique and novel.
In summary, we have extended our previous findings 
showing reprogramming of tryptophan metabolism 
in RCC leading to production of immunosuppressive 
metabolites. In this study, we have demonstrated that 
pharmacologic attenuation of this pathway in the presence 
of immunomodulatory IFNα decreases tumor growth 
in the RENCA mouse model of kidney cancer. Despite 
the absence of an effect on the composition of the tumor 
immune microenvironment in a subacute setting, MTH-
trp may alter the functionality of intratumoral leukocytes, 
setting the stage for improved therapeutic effects of IFNα. 
Due to the current clinical availability and FDA approval 
of both compounds, and the established immunogenicity 
of RCC, this work could readily and easily be translated 
into the clinic.
MATERIALS AND METHODS
Materials
Recombinant mouse IFNα-2 (eBiosciences, San 
Diego, CA), recombinant human IFNα-2a (Gemini 
Bio-Products, Sacramento, CA), recombinant mouse 
IFNγ (PeproTech, Rocky Hill, NJ) and recombinant 
human IFNγ (PeproTech) were purchased as described. 
Methyl-thiohydantoin-DL-tryptophan (MTH-trp) was 
from Cayman Chemical (Ann Arbor, MI) and dissolved 
in DMSO. L-tryptophan, kynurenine, 3-HK, kynurenic 
acid, 3-HAA, quinolinate, 1-methyl-L-tryptophan (1-L-
MT) and 1-methyl-D-tryptophan (1-D-MT) were all from 
Sigma-Aldrich (St Louis, MO). 
In vivo tumor studies
Animal experiments were performed in accordance 
with guidelines set forth by the Institutional Animal Care 
and Use Committee at UC Davis. Seven-week old male 
Balb/cJ mice (Jackson Laboratories, Bar Harbor, ME) had 
ad libitum access to food and water. For the tumor growth 
study, mice were injected with 5 x 105 RENCA cells from 
passage 7 to 11 (100 µl cells in OptiMEM with 33% BD 
Matrigel Matrix (Corning, Tewksbury, MA) SC in the 
right flank). For the flow cytometry endpoint, cells were 
passage 5. Seven days later, treatments were initiated and 
tumors measured daily with calipers. Mice were injected 
5 d/week with murine IFNα 2 (25,000 U/mouse, SC) 
or saline, and daily with MTH-trp (4 mg/mouse, IP) or 
DMSO. They were euthanized after being treated for 10 
d (flow cytometry) or 14 d (tumor burden and therapeutic 
efficacy). Resected tumors were measured, weighed, and 
volume assessed by V = 4/3*3.142*(W/2)*(L/2)*(D/2). 
Tumor pieces were frozen or fixed in 10% formalin. 
Isolation of tumor-infiltrating cells and flow 
cytometry
Tumors and spleens were homogenized into a 
suspension of single cells then stained with a panel 
of fluorochrome-conjugated antibodies to evaluate T 
cells (CD3+), B cells (CD19+), dendritic cells (CD11c+), 
granulocytes (Gr1+), monocytes (CD11b+), stromal 
cells (PDGFRα+), NK cells (NK1.1+) and NKT cells 
(CD3+/NK1.1+). CD4, CD8, Th17, and Treg T cell 
subsets, myeloid derived granulocytic and monocytic 
suppressor cell subsets, and T-cell activation status 
(naïve, conventional effector, effector memory, and 
central memory) were further characterized according to 
expression of CD25, CD69, CD62L, and CD44 on the cell 
surface and intracellular Foxp3, RORγT, IL-2, IL-10, IL-
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17, and IFNγ as previously described [33]. Stained cells 
were analyzed using a BD LSRII flow cytometer (BD 
Biosciences, San Jose, CA), and data processed using 
Flowjo software (Treestar, Ashland, OR). 
Cell culture
All cells were confirmed mycoplasma-free. Mouse 
RENCA cells (Murphy, 1973 #73) were a gift from Dr. 
Montjazeb (Dept of Radiation Oncology, University of 
California, Davis) and were verified by PCR to contain 
mouse and not human DNA (data not shown). RENCA 
cells were cultured in RPMI-1640 with 4 mM glutamine, 
10% FBS, 1x MEM non-essential amino acids, 1 
mM sodium pyruvate, 15 mM HEPES, penicillin and 
streptomycin, except for prior to high-performance liquid 
chromatography (HPLC) analysis when DMEM with 
1 mM glucose was substituted for RPMI-1640. A-498 
(VHL-), ACHN (VHL+), Caki-1 (VHL+) and 786-O 
(VHL-) cells were purchased from, and validated by, 
ATCC. These cells were cultured in DMEM with 1 mM 
glucose, 10% FBS, penicillin and streptomycin. Renal 
primary proximal tubule epithelial cells (RPTEC) were 
purchased from and validated by Lonza, and were cultured 
in renal epithelial cell growth medium (Lonza). 
Kynurenine metabolites cell growth assays
Kynurenine and 3-HK (100 mM) were prepared 
in 1M HCl, 3-HAA (50 mM) was prepared in 1M HCl, 
and kynurenic acid and quinolinic acid (100 mM) 
were prepared in 1M NaOH and stored at -20oC. Equal 
volumes of 1M HCl and 1M NaOH, with or without each 
metabolite were added to media. The media was changed 
the day following plating to medium supplemented with 
metabolites for a further three days, with medium changed 
daily. 
Methylthiazolyldiphenyl-tetrazolium bromide 
(MTT) assay
Cell viability was measured using MTT as 
previously described [34]. All values were expressed 
relative to control wells set at 100%.
IDO inhibitor cell growth assays
1-L-MT and 1-D-MT (20 mM) were prepared in 
0.1N HCl, 50% DMSO in sterile PBS. MTH-trp (100 mM) 
was prepared in DMSO. Human RCC and RENCA cells 
were treated with inhibitors or DMSO for three days. Cell 
number was determined using a methylene blue assay as 
described [35].
Immunoblotting
Immunoblotting with primary antibodies (rabbit 
polyclonal anti-human IDO1, 1:1000, Cell Signaling 
Technology, Danvers, MA; monoclonal rat anti-mouse 
IDO1, 1:500, BioLegend, San Diego, CA; monoclonal 
rabbit anti-β-actin, 1:2000, Cell Signaling Technology; 
monoclonal mouse anti-β-actin, 1:4000, Sigma-Aldrich; 
rabbit monoclonal anti-vinculin, 1:1000, Cell Signaling 
Technology) was detected by chemiluminescence as 
previously described [33]. Alternatively, fluorescence 
was quantified on the Odyssey Imaging System (Li-Cor 
BioSciences, Lincoln, Nebraska). 
Tryptophan and kynurenine quantification
Human RCC and RENCA cells were plated at sub-
confluence in 6-well plates and treated with murine IFNγ 
or human IFNγ and/or MTH-trp (100 µM) for 72 h prior 
to the collection of medium, its centrifugation (1000 g, 5 
min), and storage of supernatant at -80oC. Extraction and 
quantitation of these metabolites was as described [34].
 Immunohistochemistry
Tissue from ccRCC tumors and adjacent normal 
kidneys were archived following IRB approval at UC 
Davis Department of Pathology. Paraffin sections (4 µm) 
of formalin-fixed tissue were stained for IDO1 using 
heat-induced antigen retrieval in citrate buffer (pH 6.0) 
and anti-human IDO1 (Cell Signaling Technology), 
followed by Mach 2 Rabbit HRP-Polymer (BioCare 
Medical, Concord, CA) and ImmPACT diaminobenzidine 
peroxidase substrate (Vector Laboratories, Burlingame, 
CA). Immunohistochemistry for CD68 was done using 
heat-induced antigen retrieval at pH 9 (Dako, Carpinteria, 
CA), mouse monoclonal anti-CD68 (Leica Biosystems, 
Newcastle Upon Tyne, UK) and Mouse-on-canine HRP-
polymer (BioCare Medical) prior to detection with 
NovaRed (Vector Laboratories). A pathologist (F.U.) 
scored IDO staining using a subjective scale of 0 (no 
IDO staining) to 3 (20-40% of cells were stained) without 
assigning a grade to the tumors in order to minimize 
possible bias of the IHC analysis. No more than 40% of 
all cells in any slide stained positive. Staining of CD68 
was scored as a percentage of interstitial cells that were 
positive with a score 0 (no staining) to 5 (40-50% positive 
stained interstitial cells).
Quantitative PCR (qPCR)
Total RNA was extracted from tissue or cells 
using Trizol (Invitrogen) and its integrity confirmed 
by gel electrophoresis. Total RNA (0.5 µg) was reverse 
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transcribed in 20 µl using MultiScribe reverse transcriptase 
(Thermo Fisher Scientific; 50U). Primers for qPCR (Table 
3) were designed using Primer Blast (http://www.ncbi.
nlm.nih.gov/tools/primer-blast/) to be in different exons 
and not amplify non-specific cDNA or gDNA. This was 
confirmed by performing PCR on reverse transcription 
negative control reactions performed in the absence of 
reverse transcriptase. The tryptophan-2,3-dioxygenase 
(TDO2) and mouse glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) PCR products were confirmed 
by sequencing. Reference genes for mouse samples 
were 18S ribosomal RNA (Rn18S) and Gapdh (Table 3). 
Reference genes for human samples were cyclophilin A 
(PPIA) and ribosomal protein S13 (RPS13) as described 
by Dupasquier et al., [16; Table 3]. The cDNA was diluted 
(1:4 or 1:50) before 1 µl was analyzed using SYBR green 
PCR master mix (Applied Biosystems, Foster City, CA) 
with 0.25 µM primers on a ViiA™ 7 Real-Time PCR 
System (Applied Biosystems). Cycling conditions were 
50°C for 2 min, 95°C for 10 min then 40 cycles of 95°C 
for 15 s and 1 min at 60, 62, 63 or 64oC (Table 3). Each 
qPCR run included a no-template control containing all 
reagents except cDNA. Standard curves were prepared 
using 6 to 7 five-fold serial dilutions of either mouse or 
human liver cDNA. One standard curve was used for all 
qPCR plates within an experiment. All standard curves 
had a linear regression coefficient of determination of at 
least 99.4%. The mRNA or rRNA levels in each mouse 
sample were calculated from Ct values using a standard 
curve. The relative mRNA levels in each human sample 
were calculated from Ct values using the delta-delta Ct 
method relative to an average of the two housekeeping 
Ct values.
qPCR data normalization
Reference gene expression was normalized within 
an experiment so the average expression across all samples 
for each reference gene was the same. Normalization 
of gene expression relative to two reference genes was 
completed according to the formula [38]:
where Y is the normalized tryptophan-2,3-
dioxygenase (TDO2) or IDO1 gene expression for tissue/
cell line i, QTi is TDO2 or IDO1 mRNA quantity and QR1i 
and QR2i are reference gene quantities.
Statistical analysis
All data are expressed as mean ± standard error 
of the mean. Data for relative tumor growth and tumor 
weights were normalized using an optimal Box-Cox power 
transformation where necessary to satisfy Levene’s test for 
homogeneity of variance and analyzed in SAS 9.4 using 
the mixed procedure to fit a mixed linear model (SAS 
Institute, Inc., Cary, NC). Mouse was the experimental unit 
with treatment and RENCA cell passage number being 
fixed effects, while cage was considered a random effect. 
For all other experiments, two-tailed Students t-tests were 
used to compare means. Means were considered different 
at P < 0.05.
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